Cargando…

DCE-MRI-Derived Parameters in Evaluating Abraxane-Induced Early Vascular Response and the Effectiveness of Its Synergistic Interaction with Cisplatin

Our previous studies revealed molecular alterations of tumor vessels, varying from immature to mature alterations, resulting from Abraxane, and demonstrated that the integrin-specific PET tracer (18)F-FPPRGD2 can be used to noninvasively monitor such changes. However, changes in the tumor vasculatur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Xilin, Yang, Lili, Yan, Xuefeng, Sun, Yingying, Zhao, Dongliang, Ji, Yang, Wang, Kai, Chen, Xiaoyuan, Shen, Baozhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5025193/ https://www.ncbi.nlm.nih.gov/pubmed/27632532 http://dx.doi.org/10.1371/journal.pone.0162601

Ejemplares similares

Correction: DCE-MRI-Derived Parameters in Evaluating Abraxane-Induced Early Vascular Response and the Effectiveness of Its Synergistic Interaction with Cisplatin
por: Sun, Xilin, et al.
Publicado: (2023)

Parameters of Dynamic Contrast-Enhanced MRI as Imaging Markers for Angiogenesis and Proliferation in Human Breast Cancer
por: Li, Lin, et al.
Publicado: (2015)

Dynamic contrast enhanced (DCE) MRI estimation of vascular parameters using knowledge-based adaptive models
por: Bagher-Ebadian, Hassan, et al.
Publicado: (2023)

Integration of DCE-MRI and DW-MRI Quantitative Parameters for Breast Lesion Classification
por: Fusco, Roberta, et al.
Publicado: (2015)

Impacts of Intralipid on Nanodrug Abraxane Therapy and on the Innate Immune System
por: Chen, Yen-Ju, et al.
Publicado: (2020)

DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents
por: O'Connor, J P B, et al.
Publicado: (2007)

Robust estimation of hemo-dynamic parameters in traditional DCE-MRI models
por: Hansen, Mikkel B., et al.
Publicado: (2019)

Early Diagnosis Value of DCE-MRI Hemodynamic Parameters in Hepatocellular Carcinoma
por: Mu, Xixi, et al.
Publicado: (2022)

Molecular Imaging of IGF-1R in Cancer
por: Sun, Yingying, et al.
Publicado: (2017)

Relationship between histogram metrics of pharmacokinetic parameters of DCE-MRI and histological phenotype in breast cancer
por: Yang, Guocai, et al.
Publicado: (2020)

Synergistic effect of Abraxane that combines human IL15 fused with an albumin‐binding domain on murine models of pancreatic ductal adenocarcinoma
por: Hsu, Fei‐Ting, et al.
Publicado: (2022)

Differential study of DCE-MRI parameters in spinal metastatic tumors, brucellar spondylitis and spinal tuberculosis
por: Qiao, Pengfei, et al.
Publicado: (2018)

Maximum Entropy Technique and Regularization Functional for Determining the Pharmacokinetic Parameters in DCE-MRI
por: Amini Farsani, Zahra, et al.
Publicado: (2022)

Multiparameter MRI Model With DCE-MRI, DWI, and Synthetic MRI Improves the Diagnostic Performance of BI-RADS 4 Lesions
por: Sun, Shi Yun, et al.
Publicado: (2021)

Comparison of DCE‐MRI kinetic parameters and FMISO‐PET uptake parameters in head and neck cancer patients
por: Simoncic, Urban, et al.
Publicado: (2017)

Assessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRI
por: Guo, J, et al.
Publicado: (2015)

Phantom Validation of DCE-MRI Magnitude and Phase-Based Vascular Input Function Measurements
por: Foltz, Warren, et al.
Publicado: (2019)

Albumin-bound formulation of paclitaxel (Abraxane(®) ABI-007) in the treatment of breast cancer
por: Miele, Evelina, et al.
Publicado: (2009)

Correlations Between DCE MRI and Histopathological Parameters in Head and Neck Squamous Cell Carcinoma()
por: Surov, Alexey, et al.
Publicado: (2016)

Correlation of DCE-MRI Perfusion Parameters and Molecular Biology of Breast Infiltrating Ductal Carcinoma
por: Liu, Li, et al.
Publicado: (2021)

Comparison of Ultrafast Dynamic Contrast-Enhanced (DCE) MRI with Conventional DCE MRI in the Morphological Assessment of Malignant Breast Lesions
por: Ohashi, Akane, et al.
Publicado: (2023)

Abraxane, the Nanoparticle Formulation of Paclitaxel Can Induce Drug Resistance by Up-Regulation of P-gp
por: Zhao, Minzhi, et al.
Publicado: (2015)

Breast MR with special focus on DW-MRI and DCE-MRI
por: Petralia, G., et al.
Publicado: (2011)

Impact of (k,t) sampling on DCE MRI tracer kinetic parameter estimation in digital reference objects
por: Bliesener, Yannick, et al.
Publicado: (2019)

nab-Paclitaxel (Abraxane(®)): an albumin-bound cytotoxic exploiting natural delivery mechanisms into tumors
por: Iglesias, J
Publicado: (2009)

Surrogate vascular input function measurements from the superior sagittal sinus are repeatable and provide tissue-validated kinetic parameters in brain DCE-MRI
por: Lewis, Daniel, et al.
Publicado: (2022)

The clinical value of DCE-MRI for differentiating secondary laryngeal cartilage lesions
por: Yu, Jinfen, et al.
Publicado: (2023)

Assessment of cardiac RF ablation lesions by DCE-MRI
por: Vijayakumar, Sathya, et al.
Publicado: (2014)

Dependence of DCE-MRI biomarker values on analysis algorithm
por: Ng, Chaan S., et al.
Publicado: (2015)

DCE-MRI of Tumor Hypoxia and Hypoxia-Associated Aggressiveness
por: Gaustad, Jon-Vidar, et al.
Publicado: (2020)

Editorial: Use of DCE-MRI in female affecting cancers
por: Romeo, Valeria, et al.
Publicado: (2023)

DCE-MRI Perfusion and Permeability Parameters as predictors of tumor response to CCRT in Patients with locally advanced NSCLC
por: Tao, Xiuli, et al.
Publicado: (2016)

DCE-MRI of patient-derived xenograft models of uterine cervix carcinoma: associations with parameters of the tumor microenvironment
por: Hauge, Anette, et al.
Publicado: (2017)

Aberrant glioblastoma neovascularization patterns and their correlation with DCE-MRI-derived parameters following temozolomide and bevacizumab treatment
por: Xue, Wei, et al.
Publicado: (2017)

Evaluating the scope of intramedullary invasion of malignant bone tumor by DCE-MRI quantitative parameters in an animal study
por: Zhang, Yuan, et al.
Publicado: (2019)

Characterizing Errors in Pharmacokinetic Parameters from Analyzing Quantitative Abbreviated DCE-MRI Data in Breast Cancer
por: Slavkova, Kalina P., et al.
Publicado: (2021)

Preclinical efficacy studies of a novel nanoparticle-based formulation of paclitaxel that out-performs Abraxane
por: Feng, Zhongling, et al.
Publicado: (2009)

A Paclitaxel-Loaded Recombinant Polypeptide Nanoparticle Outperforms Abraxane in Multiple Murine Cancer Models
por: Bhattacharyya, Jayanta, et al.
Publicado: (2015)

Recombinant nanocomposites by the clinical drugs of Abraxane(®) and Herceptin(®) as sequentially dual-targeting therapeutics for breast cancer
por: Ding, Shuang, et al.
Publicado: (2018)

Clinical comparative investigation of efficacy and toxicity of cisplatin plus gemcitabine or plus Abraxane as first-line chemotherapy for stage III/IV non-small-cell lung cancer
por: Ai, Dan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_p09nq12d8dj4g5bph179lacvt4